Literature DB >> 3263962

Opposite effects of EGF on involucrin accumulation of A431 keratinocytes and a variant which is not growth-arrested by EGF.

M Rosdy1.   

Abstract

The A431 cell line is composed of malignant keratinocytes derived from a vulval epidermoïd carcinoma. These cells have the peculiarity to stop their proliferation when they are treated with physiological concentrations of EGF, which is a mitogen for normal keratinocytes. We reported earlier that EGF induces involucrin accumulation in A431 cells and proposed that the arrest of proliferation triggers differentiation as shown by the induction of this cornified envelope precursor protein. To test this hypothesis, we compared the A431 subclone 15, which is not growth arrested by EGF-treatment, to the parental A431 cells. We found indeed that EGF reduces the involucrin content of clone 15 cells in a dose dependent manner. These opposite effects of EGF on the expression of terminal differentiation marker involucrin in A431 and A431 clone 15 keratinocytes were observed in defined medium as well as in presence of fetal calf serum. Nevertheless, when growth of parental A431 cells was inhibited by treatment with TGF-beta or simply when cultures reached confluency, no involucrin accumulation was observed. Therefore growth arrest per se is not directly correlated with the induction of differentiation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263962     DOI: 10.1007/bf02620815

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  31 in total

1.  Two functionally distinct classes of growth arrest states in human prokeratinocytes that regulate clonogenic potential.

Authors:  M R Pittelkow; J J Wille; R E Scott
Journal:  J Invest Dermatol       Date:  1986-04       Impact factor: 8.551

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Analysis of morphology and receptor metabolism in clonal variant A431 cells with differing growth responses to epidermal growth factor.

Authors:  A Lifshitz; C S Lazar; J E Buss; G N Gill
Journal:  J Cell Physiol       Date:  1983-06       Impact factor: 6.384

5.  Retinoid suppression of transglutaminase activity and envelope competence in cultured human epidermal carcinoma cells. Hydrocortisone is a potent antagonist or retinyl acetate but not retinoic acid.

Authors:  S M Thacher; E L Coe; R H Rice
Journal:  Differentiation       Date:  1985       Impact factor: 3.880

6.  Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.

Authors:  T Kawamoto; J D Sato; A Le; J Polikoff; G H Sato; J Mendelsohn
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

7.  Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture.

Authors:  S T Boyce; R G Ham
Journal:  J Invest Dermatol       Date:  1983-07       Impact factor: 8.551

8.  Stimulation and inhibition of growth by EGF in different A431 cell clones is accompanied by the rapid induction of c-fos and c-myc proto-oncogenes.

Authors:  R Bravo; J Burckhardt; T Curran; R Müller
Journal:  EMBO J       Date:  1985-05       Impact factor: 11.598

9.  Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture.

Authors:  D W Barnes
Journal:  J Cell Biol       Date:  1982-04       Impact factor: 10.539

10.  Involucrin synthesis is correlated with cell size in human epidermal cultures.

Authors:  F M Watt; H Green
Journal:  J Cell Biol       Date:  1981-09       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.